16 August 2010

Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010

Southern Cross Equities Research – Big Pharma will be watching

21 July 2010

Southern Cross Equities Research – The clinical endgame nears

17 May 2010

Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010

Bioshares

12 May 2010

Biotech Daily

26 February 2010

RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

22 January 2010

RBS Equities Research: Mesoblast - Analysis of MSB’s Opportunities

8 January 2010

Southern Cross Equities Research: Mesoblast – The Stem Cell Opportunity

22 December 2009

RBS Equities Research: Diabetes - An Expanding Portfolio

20 December 2009

Bioshares: Stock Picks 2010

16 October 2009

Bioshares

9 October 2009

Bioshares

3 August 2009

Bioshares

15 May 2009

Bioshares

30 March 2009

RBS Equities Research

17 March 2009

Lodge Partners Research Report

27 February 2009

ABN AMRO Equity Research

27 February 2009

Bioshares

05 December 2008

Bioshares

07 November 2008

Bioshares

28 August 2008

ABN Amro Equity Research

20 June 2008

Bioshares

June 2008

OzEquities

20 June 2008

Bioshares

30 April 2008

ABN Amro Research Note

19 February 2008

ABN Amro Research Note

23 January 2008

Lodge Partners Research Report

29 August 2007

ABN Amro Research Report

21 August 2007

Lodge Partners Research -Initiation of coverage

06 April 2006

Ord Minnett research report

13 May 2005

Bioshares

 

Investor Centre


 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine